| Literature DB >> 32028090 |
Pedro Bernal1, Sebastian Martinez2.
Abstract
We experimentally evaluated the effects of in-kind team incentives on health worker performance in El Salvador, with 38 out of 75 community health teams randomly assigned to performance incentives over a 12-month period. All teams received monitoring, performance feedback and recognition for their achievements allowing us to isolate the effect of the incentive. While both treatment and control groups exhibit improvements in performance measures over time, the in-kind incentives generated significant improvements in community outreach, quality of care, timeliness of care, and utilization of maternal and child health services after 12 months. Gains were largest for teams at the bottom and top of the baseline performance distribution. We find no evidence of results being driven by changes in reporting or by shifting away effort from non-contracted outcomes. These results suggest that in-kind team incentives may be a viable alternative to monetary or individual incentives in certain contexts.Entities:
Keywords: El Salvador; Health services; In-kind; Pay for performance; Performance incentives; Team incentives
Mesh:
Year: 2019 PMID: 32028090 PMCID: PMC7188218 DOI: 10.1016/j.jhealeco.2019.102267
Source DB: PubMed Journal: J Health Econ ISSN: 0167-6296 Impact factor: 3.883
Indicators used to evaluate team performance, targets, and source of verification.
| Category | Indicator | Target | Points | Source |
|---|---|---|---|---|
| Outreach | Women 15–49 receiving information on modern family planning methods by health personnel in the last six months | 80% | 5 | Household survey |
| Outreach | Women 15–49 with children less than five with knowledge of treatment of diarrhea with oral rehydration salts and zinc at the time of the survey | 50% | 10 | Household survey |
| Quality | Prenatal care according to national clinical guidelines for women with a delivery in the last four months | 80% | 10 | Medical Records |
| Quality | Reference to institutional delivery in birth plan for women with a delivery in the last four months | 100% | 5 | Medical Records |
| Timeliness | First prenatal care visit prior to 12 weeks of gestation for women with pregnancies that reached three months of gestation in the last six months | 80% | 10 | Medical Records |
| Timeliness | Postpartum care within a week from delivery by health personnel for women with a delivery in the last four months | 92% | 10 | Medical Records |
| Utilization | Women 15–49 in need of family planning using a modern family planning method at the time of the survey | 61% | 15 | Household survey |
| Utilization | Institutional Delivery for women with a delivery in the last four months | 94% | 10 | Medical Records |
| Utilization | Prescription of micronutrients for children 6–23 months old in the last six months1/ | 80% | 15 | Medical Records |
| Utilization | Consumption of two deworming pills in the last six months by children 18–59 months old2/ | 80% | 5 | Household survey |
| Utilization | Children 12–23 months with vaccination of measles, mumps, and rubella (MMR) | 80% | 5 | Medical Records |
| Total points | 100 |
Notes: The target is the one set by the MoH for the indicator in order to receive the points towards the performance score. The points are the ones awarded to the performance score if the target was met. The source describes the verification source for the target. The detailed definition of each indicator can be found in Table A2 in the Appendix. Prescription of micronutrients is included in the utilization category since the underlying outcome of interest was to improve the consumption of micronutrients sachets, but no feasible indicators could be used other than this.
1/ This definition was changed to micronutrients provided to children 6–23 months in the last six months after baseline since it was considered a better proxy. The definition provided in the table was the one used in the analysis since it had baseline data.
2/ At baseline the source of verification was the clinical record of children but was changed to vaccination records after baseline since it was considered more comprehensive.
Sliding scale to determine the amount of the incentive obtained in each cycle.
| Points obtained1/ | % of Incentive | Incentive amount (USD) |
|---|---|---|
| 90–100 | 100% | $1000 |
| 80–89 | 85% | $850 |
| 70–79 | 75% | $750 |
| 60–69 | 65% | $650 |
| 59 or less | 0% | $0 |
1/ The points obtained are calculated by dividing the total points obtained in each external verification cycle by the total number of points possible, i.e. excluding those indicators with no data and multiplying it times 100.
Fig. 1Team performance reports & certificates by treatment status.
Notes: The top part of the figure presents a sample of the cover page of the performance report for each team. Highlighted in orange are the differences between the two. The bottom part of the figure presents a sample of the certificates of performance that were provided to teams that obtained 60% of more of the total points possible. The differences between the two are the amount obtained in treatment teams and the title of the certificate (a voucher in the case of treatment and just certificate for control). The identity of the teams was masked for confidentiality purposes.
Fig. 2Distribution of team performance scores by treatment status and time period.
Notes: The graphs present the kernel density of the distribution of the performance score of all teams by treatment assignment. The score is calculated as explained in Section 3 and was the one informed to teams during the period. The exact p-value of the Kolmogorov-Smirnov test of equality of the treatment and control distributions in each period is presented on the second column. During the 6th and 12th month follow-ups the experimental only treatment teams received incentives. At the 18th month follow-up both treatment and control teams were eligible for incentives.
Treatment Effect by Domain.
| Baseline | Post-treatment (No controls) | Post-treatment (Controlling for Baseline) | |
|---|---|---|---|
| (1) | (2) | (3) | |
| 0.0358 | 0.1763** | 0.1748** | |
| (0.069) | (0.071) | (0.069) | |
| p-value | [0.603] | [0.013] | [0.011] |
| −0.1361 | 0.1349** | 0.1427*** | |
| (0.095) | (0.058) | (0.054) | |
| p-value | [0.152] | [0.020] | [0.008] |
| 0.0954 | 0.1203** | 0.1021* | |
| (0.089) | (0.057) | (0.052) | |
| p-value | [0.286] | [0.035] | [0.051] |
| −0.0323 | 0.0897** | 0.0958** | |
| (0.065) | (0.041) | (0.040) | |
| p-value | [0.620] | [0.028] | [0.015] |
| 0.0937* | 0.0379 | 0.0215 | |
| (0.053) | (0.035) | (0.031) | |
| p-value | [0.079] | [0.274] | [0.485] |
| Community Health Teams | 64 | 64 | 64 |
Notes: The analysis sample is the 64 teams with data in all waves. For each domain, the table presents the estimate of the average standardized treatment effect (ASTE) as described in Eq. (2) using the individual outcomes as described in Table 1. Column (1) presents the estimate of from baseline on the outcome of interest using Eq. (1),but excluding any baseline covariates. Column (2) presents the estimate of using the pooled 6th and 12th month follow-up data excluding baseline covariates. Column (3) presents the same estimate as (3) but includes as baseline covariate the mean team level outcome of interest at baseline. All estimates are with individual level data. Details of the sample of interest for each indicator is in Table A8 in the Appendix. Standard errors are clustered at the team level and are presented in parenthesis. P-values are included in square brackets.
*p < 0.10, ** p < 0.05, *** p < 0.01.
Fig. 3Average standardized treatment effect of all contracted outcomes by category of baseline performance score.
Notes: Categories of baseline performance score are constructed based on the sliding scale for incentives. The first category includes teams with a baseline performance below the threshold for incentives, i.e., 60. The second category includes teams just at or above the incentive threshold, i.e. 60–69 inclusive. The third category includes those teams with a baseline performance score of 70 or higher. The number of teams in each category is displayed in the figure label. Average standardized treatment effect of all eleven contracted outcomes, obtained as described in Section 5, using the model that pools both the 6th and 12th month follow-ups and with block effects and the baseline value of the outcome of interest in each regression. Confidence interval at 95% constructed from standard errors clustered at the team level, displayed on the red lines around each estimate.
Heterogeneity of treatment effects by performance score at baseline.
| Post-treatment (Controlling for Baseline) | ||||
|---|---|---|---|---|
| Baseline Performance Score Category | ||||
| Overall | 0-59 | 60–69 | 70-100 | |
| (1) | (2) | (3) | (4) | |
| 0.1748** | 0.2615*** | −0.1132 | 0.3374** | |
| (0.069) | (0.096) | (0.105) | (0.141) | |
| p-value | [0.011] | [0.006] | [0.280] | [0.017] |
| 0.1427*** | 0.1330* | 0.0706 | 0.1268 | |
| (0.054) | (0.071) | (0.090) | (0.119) | |
| p-value | [0.008] | [0.061] | [0.431] | [0.288] |
| 0.1021* | 0.0859 | −0.0328 | 0.2854*** | |
| (0.052) | (0.058) | (0.139) | (0.093) | |
| p-value | [0.051] | [0.140] | [0.814] | [0.002] |
| 0.0958** | 0.0691 | 0.0217 | 0.1925*** | |
| (0.040) | (0.070) | (0.067) | (0.049) | |
| p-value | [0.015] | [0.326] | [0.747] | [0.000] |
| 0.0215 | 0.0419 | −0.0074 | 0.0070 | |
| (0.031) | (0.049) | (0.073) | (0.037) | |
| p-value | [0.485] | [0.387] | [0.919] | [0.852] |
| Community Health Teams | 64 | 30 | 19 | 15 |
Notes: The sample of analysis is of the 64 teams with data on all waves. Column (1) presents the estimates of the average standardized treatment effect (ASTE) post-treatment controlling for team-level baseline outcomes by domain, as presented on Panel A, Column (4) of Tables 3 through 7. Column (2) presents results for teams below the cutoff for incentives in their performance score at baseline. Column (3) presents results for teams with a baseline performance score of 60–69, which is equivalent for the first bracket of the incentive scheme. Column (4) presents results for teams with the highest levels of performance score at baseline (70–100). The performance score is defined as in Section 3. Standard errors are clustered at the team level and are presented in parenthesis. P-values are included in square brackets.
*p < 0.10, ** p < 0.05, *** p < 0.01.
Comparison of individual outcome effects by source.
| Common Sample of Units & Time-Periods | |||||
|---|---|---|---|---|---|
| Medical Records Proxy | Household Survey | ||||
| Control Mean | Post-treatment (Controlling for Baseline) | Control Mean | Post-treatment (Controlling for Baseline) | P-value of difference between (2) and (4) | |
| (1) | (2) | (3) | (4) | (5) | |
| 0.7109 | 0.0259 | 0.5746 | −0.0000 | ||
| (0.034) | (0.072) | ||||
| p-value | [0.450] | [1.000] | [0.717] | ||
| N | 927 | 276 | |||
| Units | 33 | 33 | |||
| 0.6080 | 0.1213** | 0.9167 | 0.0563** | ||
| (0.051) | (0.021) | ||||
| p-value | [0.025] | [0.012] | [0.228] | ||
| N | 675 | 275 | |||
| Units | 33 | 33 | |||
| 0.7557 | 0.0307 | 0.9167 | 0.0068 | ||
| (0.037) | (0.031) | ||||
| p-value | [0.414] | [0.829] | [0.566] | ||
| N | 675 | 276 | |||
| Units | 33 | 33 | |||
| 0.6364 | 0.0538 | 0.8611 | 0.0752 | ||
| (0.051) | (0.062) | ||||
| p-value | [0.295] | [0.235] | [0.803] | ||
| N | 1,105 | 154 | |||
| Units | 33 | 33 | |||
Notes: The analysis sample is 33 teams with data in all waves for both households and medical records. All outcomes include common cohorts of patients for medical records and household surveys. Columns (2) and (4) present the estimates of the treatment effect (ASTE) post-treatment controlling for the team-level baseline of the outcome. Standard errors are clustered at the team level and are presented in parenthesis. P-values are included in square brackets.
*p < 0.10, ** p < 0.05, *** p < 0.01.